Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

4

US Approved Rx

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Serotonin 2c (5-HT2c) receptor

4

GABA-A receptor; anion channel

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2011

1

2012

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Obesity

4

Lennox-Gastaut syndrome

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

4

Secondary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

5

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Arena Pharmaceuticals

4

Maestretti Research Laboratories

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

5

PUBCHEM

5

CAS

4

CHEBI

4

DRUG BANK

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS

1

PSYCHOLEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS

1

ANXIOLYTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Benzodiazepine derivatives

1

Centrally acting antiobesity products

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CLOBAZAM

2MRO291B4U

Export Data
Search for Structure

Status:

US Approved Rx (2012)

First approved in 2011

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

GABA-A receptor; anion channel

Conditions:

Lennox-Gastaut syndrome

Clobazam belongs to the 1,5-benzodiazepine class of drugs with antiepileptic properties. It has been used to treat anxiety and epilepsy since 1970s. In the US clobazam was approved for marketing in October of 2011 for the adjunctive treatment of seiz...

ures associated with Lennox-Gastaut syndrome. It is also approved for adjunctive therapy for epilepsy in patients who have not responded to first-line drugs and in children who are refractory to first-line drugs. The mechanism of action for clobazam is not fully understood but is thought to involve what is known as potentiation of GABAergic neurotransmission resulting from binding at a benzodiazepine site at the GABA(A) receptor. Possible side effects: constipation, fever, drowsiness, sedation, ataxia, aggressive behavior, lethargy, drooling, and irritability. Other side effects include: urinary tract infection, pneumonia, cough, dysphagia, dysarthria, bronchitis, insomnia, fatigue, decreased appetite, and increased appetite.

LORCASERIN

637E494O0Z

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 2012

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Serotonin 2c (5-HT2c) receptor

Conditions:

Lorcaserin, currently marketed under the trade name Belviq and previously Lorqess during development, is a weight-loss drug developed by Arena Pharmaceuticals. Lorcaserin is a selective 5-HT2C receptor agonist, and in vitro testing of the drug showed...

reasonable selectivity for 5-HT2C over other related targets. 5-HT2C receptors are located almost exclusively in the brain, and can be found in the choroid plexus, cortex, hippocampus, cerebellum, amygdala, thalamus, and hypothalamus. The activation of 5-HT2C receptors in the hypothalamus is supposed to activate proopiomelanocortin (POMC) production and consequently promote weight loss through satiety. This hypothesis is supported by clinical trials and other studies. While it is generally thought that 5-HT2C receptors help to regulate appetite as well as mood, and endocrine secretion, the exact mechanism of appetite regulation is not yet known. Lorcaserin has shown 100x selectivity for 5-HT2C versus the closely related 5-HT2B receptor, and 17x selectivity over the 5-HT2A receptor

LORCASERIN HYDROCHLORIDE, ADSORBED ON SILICON DIOXIDE (1:2 W/W)

3423KE0K4Y

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 2012

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Serotonin 2c (5-HT2c) receptor

Conditions:

Lorcaserin, currently marketed under the trade name Belviq and previously Lorqess during development, is a weight-loss drug developed by Arena Pharmaceuticals. Lorcaserin is a selective 5-HT2C receptor agonist, and in vitro testing of the drug showed...

reasonable selectivity for 5-HT2C over other related targets. 5-HT2C receptors are located almost exclusively in the brain, and can be found in the choroid plexus, cortex, hippocampus, cerebellum, amygdala, thalamus, and hypothalamus. The activation of 5-HT2C receptors in the hypothalamus is supposed to activate proopiomelanocortin (POMC) production and consequently promote weight loss through satiety. This hypothesis is supported by clinical trials and other studies. While it is generally thought that 5-HT2C receptors help to regulate appetite as well as mood, and endocrine secretion, the exact mechanism of appetite regulation is not yet known. Lorcaserin has shown 100x selectivity for 5-HT2C versus the closely related 5-HT2B receptor, and 17x selectivity over the 5-HT2A receptor

LORCASERIN HYDROCHLORIDE HEMIHYDRATE

REV26SR2B4

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 2012

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Serotonin 2c (5-HT2c) receptor

Conditions:

Lorcaserin, currently marketed under the trade name Belviq and previously Lorqess during development, is a weight-loss drug developed by Arena Pharmaceuticals. Lorcaserin is a selective 5-HT2C receptor agonist, and in vitro testing of the drug showed...

reasonable selectivity for 5-HT2C over other related targets. 5-HT2C receptors are located almost exclusively in the brain, and can be found in the choroid plexus, cortex, hippocampus, cerebellum, amygdala, thalamus, and hypothalamus. The activation of 5-HT2C receptors in the hypothalamus is supposed to activate proopiomelanocortin (POMC) production and consequently promote weight loss through satiety. This hypothesis is supported by clinical trials and other studies. While it is generally thought that 5-HT2C receptors help to regulate appetite as well as mood, and endocrine secretion, the exact mechanism of appetite regulation is not yet known. Lorcaserin has shown 100x selectivity for 5-HT2C versus the closely related 5-HT2B receptor, and 17x selectivity over the 5-HT2A receptor

LORCASERIN HYDROCHLORIDE ANHYDROUS

0QJF08GDPE

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 2012

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Serotonin 2c (5-HT2c) receptor

Conditions:

Lorcaserin, currently marketed under the trade name Belviq and previously Lorqess during development, is a weight-loss drug developed by Arena Pharmaceuticals. Lorcaserin is a selective 5-HT2C receptor agonist, and in vitro testing of the drug showed...

reasonable selectivity for 5-HT2C over other related targets. 5-HT2C receptors are located almost exclusively in the brain, and can be found in the choroid plexus, cortex, hippocampus, cerebellum, amygdala, thalamus, and hypothalamus. The activation of 5-HT2C receptors in the hypothalamus is supposed to activate proopiomelanocortin (POMC) production and consequently promote weight loss through satiety. This hypothesis is supported by clinical trials and other studies. While it is generally thought that 5-HT2C receptors help to regulate appetite as well as mood, and endocrine secretion, the exact mechanism of appetite regulation is not yet known. Lorcaserin has shown 100x selectivity for 5-HT2C versus the closely related 5-HT2B receptor, and 17x selectivity over the 5-HT2A receptor

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1